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Abstract Two splice variants of the 5-HT7 receptor were 
identified in human brain that differ in the lengths of their 
intracellular carboxy terminal tail. Identification of the variants 
of this receptor is of particular interest since the 5-HT7 receptor 
is known to have a high affinity for a number of antidepressants 
and is localized in brain regions thought to be implicated in 
depression. The two isoforms are expressed in roughly equal 
amounts in various regions of the human brain. When expressed 
in NIH-3T3 cells, both variants encode functional 5-HT7 
receptors, positively coupled to adenylyl cyclase. We suggest 
that both variants are derived from a single gene by alternative 
mRNA splicing. Furthermore, our results from Southern blot 
analysis studies suggest that additional 5-HT7 receptor genes 
may exist in human. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmit-
ter that has been implicated in a wide diversity of behavioural 
and physiological processes [1]. Molecular cloning studies 
have indicated the existence of 14 different genes, each encod-
ing a distinct 5-HT receptor subtype (reviewed in [2]). All of 
these, with the exception of the 5-HT3 receptor belong to the 
family of G-protein-coupled receptors. These receptor sub-
types differ with respect to tissue distribution, ligand-binding 
characteristics, and coupling to intracellular second-messenger 
systems. On the basis of molecular and pharmacological cri-
teria, these subtypes have been classified into seven main 
classes: 5-HTj to 5-HT7 [2]. 
For many neurotransmitter receptors, the molecular diver-
sity is further increased by the occurrence of splice variants 
and receptor isoforms of a particular receptor subtype. In case 
of the 5-HT4 receptor, for example, two different m R N A 
splice variants have been identified encoding proteins which 
differ at their C-termini [3]. These splice variants vary both in 
tissue distribution and in c A M P coupling [3]. Furthermore, 
for the prostaglandin EP 3 receptor and the somatostatin S2 
receptor isoforms have been identified that differ at their C-
terminal tails due to alternative splicing, activating different 
G-proteins and intracellular second-messenger systems [4,5]. 
Among the dopamine receptors, the D 4 receptor subtype is 
unique in that a large number of polymorphic variants of this 
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receptor has been identified in the human populat ion [6,7]. 
The most extensive polymorphism is a 48-bp tandem repeat 
located within the third cytoplasmic loop of the receptor [6,7]. 
In this study we report the cloning of two cDNAs for 5-
H T 7 receptor variants from human brain. The identification 
of variants of the 5-HT7 receptor subtype is of particular 
interest since this receptor is thought to be localized to limbic 
and cortical regions of the brain [8-12]. Moreover, this recep-
tor shows a high affinity for serotonin as well as for a number 
of tricyclic antipsychotic and antidepressant drugs [8-12]. The 
existence of a variant of this receptor in human brain may 
have therapeutical implications for the treatment of psychiat-
ric diseases. We show that the two isoforms are co-expressed 
at similar levels in various brain regions. Furthermore, using 
ligand-binding and functional studies we show that both ver-
sions of the receptor encode functional receptors that increase 
adenylyl cyclase activation. 
2. Materials and methods 
2.1. General methods 
All general recombinant DNA procedures were performed as de-
scribed by Sambrook et al. [13]. Restriction endonucleases were pur-
chased from Pharmacia, radiolabeled nucleotides were from Du Pont 
(NEN). DNA sequencing was carried out with the Auto Read se-
quencing kit (Pharmacia) or with the Cycle Sequencing with Fluores-
cent labelled primer kit (Amersham) and either M13 forward or re-
verse oligonucleotide primers or specific primers. 
2.2. Oligonucleotides and probes 
Sequence primers and oligonucleotides for polymerase chain reac-
tion (PCR) experiments were synthesised on the basis of the published 
sequence of the human 5-HT'/ gene [8]. The nucleotides corresponding 
to the 5-HT7-specific primers are indicated below. Org 2518: 5'-GA-
CCCTGTGCGTGATCAGCATCGACAGGTA (sense, 513-542); 
Org 2901: 5' -CATGACGGATCCTTCTGCTTTCAATCATGAAT-
CATGACCTT (antisense, 1322-1350); Org 3077: 5'-GGCGCGAT-
GATGGACGTTAA (sense, - 6 to 14); Org 3078: 5'-TCACTATGC-
CATTCAGGGCG (antisense, 861-880); Org 3588: 5'-GCTCCA-
GTGCCAGTACCGGA (sense 1194-1213). 
Sequence primers: Org 3579: 5'-AGGGTTAATGAGAGAGTTT-
G (antisense, 1124-1143); Org 3580: 5'-CGACAGCCAGACCCTT-
CATC (sense, 1040-1059); Org 3581: 5'-GAGGTAAGGTGATGG-
AGGCG (antisense, 630-649); Org 3582: 5'-TCCGCCAGCCCTC-
CAACTAC (sense, 335-354); Org 3594: 5'-GTGGCTGCTTTCTG-
TTCTCG (antisense, 961-980). 
The probes used for Southern blot analysis were generated by re-
striction enzyme digestions. Probe 1 corresponds to nucleotides 
1-836. Probe 2 corresponds to nucleotides 836-1258. 
2.3. PCR amplification and cloning of the 5-HTi gene 
First-strand cDNA was synthesized from 5 ug Poly(A+) hippocam-
pal RNA in a 20 ul reaction volume as described elsewhere [14]. The 
coding sequence of the 5-HT7 receptor was amplified in two parts 
from human hypothalamic cDNA with the polymerase chain reaction 
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technique [8]. For the 5' part of the gene the primer set Org 3077/3078 
was used and for the 3' part Org 2518/2901. The sequence of the 
primers is given above. The PCR reaction (35 cycles of 94°C for 30 
s, 55°C for 30 s and 72°C for 1 min with a Perkin Elmer Cetus 9600 
thermal cycler) was performed using human hypothalamic cDNA as a 
template. The PCR amplification of the 5' part of the gene was car-
ried out under the following conditions: 20 mM Tris-HCl, pH 8.8; 10 
mM KC1; 10 mM (NH4)2S04; 2 mM MgS04 ; 0.1% Triton X-100; 
0.1 mg/ml bovine serum albumin (BSA); 3% DMSO; 0.2 mM of each 
of the deoxynucleotide triphosphates and 2.5 U of cloned Pfu DNA 
polymerase (Stratagene) in a total volume of 100 ill. 
For the 3' part of the gene the Advantage cDNA PCR kit (Clon-
tech) was used. The PCR products were analysed by gel electropho-
resis on a 1% agarose gel and ethidium bromide staining. The bands 
were recovered from the gel with the Qiaex II gel extraction kit (Qia-
gen) and cloned into the pCRII vector (Invitrogen) for sequencing. 
2.4. Subcloning of the 5-HTf gene into the eukaryotic expression vector 
pKCRE 
To facilitate subcloning of the intact coding sequence of the 5-HT7 
receptor into the BamHl site of the eukaryotic expression vector 
pKCRE, the PCR amplified 5' and 3' ends of the coding sequence 
were ligated and subcloned into the vector pGEM4Z. In case of the 5' 
end, the R-oRI site of the pCRII vector and the unique internal Xhol 
site were used. For the 3' part, the same internal Xhol site and a 
BamHI site that was introduced at the 3' end by PCR were used. 
Subsequently, the construct pi was digested with EcoKl and AccI, 
the 5-HT7 insert was blunt ended with T4-DNA polymerase and li-
5 - H T 7 L 
ATGATGGACGTTAACAGCAGCGGCCGCCCGGACCTCTACGGGCACCTCCGCTCTTTCCTTCTGCCAGAAGTGGGGCGCGGGCTGCCCGAC 
M M D V N S S G R P D L Y G H L R S F L L P E V G R G L P D 
90 
30 
TTGAGCCCCGACGGTGGCGCCGACCCGGTCGCGGGCTCCTGGGCGCCGCACCTGCTGAGCGAGGTGACAGCCAGCCCGGCGCCCACCTGG 
L S P D G G A D P V A G S W A P H L L S E V T A S P A P T W 
h-
GACGCGCCCCCGGACAATGCCTCCGGCTGTGGGGAACAGATCAACTACGGCAGAGTCGAGAAAGTTGTGATCGGCTCCATCCTGACGCTC 
D A P P D N A S G C G E Q I N Y G R V E K V V I G S I L T L 
I 1 I 
ATCACGCTGCTGACGATCGCGGGCAACTGCCTGGTGGTGATCTCCGTGTGCTTCGTCAAGAAGCTCCGCCAGCCCTCCAACTACCTGATC 
I T L L T I A G N C L V V I S V C F V K K L R Q P S N Y L I 
n 1 
GTGTCCCTGGCGCTGGCCGACCTCTCGGTGGCTGTGGCGGTCATGCCCTTCGTCAGCGTCACCGACCTCATCGGGGGCAAGTGGATCTTT 
V S L A L A D L S V A V A V M P F V S V T D L I G G K W I F 
1 in 1 
GGACACTTTTTCTGTAATGTCTTCATCGCCATGGACGTCATGTGCTGCACGGCCTCGATCATGACCCTGTGCGTGATCAGCATTGACAGG 
G H F F C N V F I A M D V M C C T A S I M T L C V I S I D R 
I IV 
TACCTTGGGATCACAAGGCCCCTCACATACCCTGTGAGGCAGAATGGGAAATGCATGGCGAAGATGATTCTCTCCGTCTGGCTTCTCTCC 
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GCCTCCATCACCTTACCTCCACTCTTTGGATGGGCTCAGAATGTAAATGATGATAAGGTGTGCTTGATCAGCCAGGACTTTGGCTATACG 
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V 1 
ATTTACTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGCTTTTCATGTACTACCAGATTTACAAGGCTGCCAGGAAGAGTGCT 
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I 
GAGTGTGCAAACCTTTCGAGACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAAGCGAGAACAGAAAGCAGCCACCACCCTGGGG 990 
E C A N L S R L L K H E R K N I S I F K R E Q K A A T T L G 330 
VI 1 
ATCATCGTCGGGGCCTTTACCGTGTGCTGGCTGCCATTTTTCCTCCTCTCGACAGCCAGACCCTTCATCTGTGGCACTTCCTGCAGCTGC 1080 
I I V G A F T V C W L P F F L L S T A R P F I C G T S C S C 360 
1 vn 1 
ATCCCACTGTGGGTGGAGAGGACATTTCTGTGGCTAGGCTATGCAAACTCTCTCATTAACCCTTTTATATATGCCTTCTTCAACCGGGAC 1170 
I P L W V E R T F L W L G Y A N S L I N P F I Y A F F N R D 390 
CTGAGGACCACCTATCGCAGCCTGCTCCAGTGCCAGTACCGGAATATCAACCGGAAGCTCTCAGCTGCAGGCATGCATGAAGCCCTGAAG 1260 
L R T T Y R S L L Q C Q Y R N I N R K L S A A G M H E A L K 420 
.CAAAATGCTGACTACTGTAGAAAAAAAGGTCATGATTCAtgattgaaagc 1347 
CTTGCTGAGAGGCCAGAGAGACCTGAGTTTGTGCT 
L A E R P E R P E F V L 
ACAAAATGCTGAI 
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Fig. 1. Nucleotide and deduced amino acid sequences of the cDNAs for 5-HT7L and 5-HT7S isoforms. The complete nucleotide sequence of the 
5-HT7L isoform is shown, followed by the 3' end of the 5-HT7s variant (boxed). Deduced amino acids are shown in single letter code below 
the nucleotide sequence. The seven putative transmembrane domains are indicated by I-VII. 
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Fig. 2. Analysis of the relative expression patterns of the 5-HT7L and 5-HT7s variants in various human tissues. Poly(A
+) RNA prepared from 
the tissues indicated was copied with reverse transcriptase and submitted to PCR. The primers were directed against two specific regions of the 
5-HT7 receptor sequence that are conserved between the two isoforms. Samples 7 and 8 represent controls with plasmid DNA containing indi-
vidual 5-HT7L and 5-HT7S receptor DNAs, respectively. Samples 5 and 9 contain plasmid DNA of the long and short variants in a 1:1 molec-
ular ratio. 
gated into the blunted BamHl site of pKCRE. The 5-HT7 gene splice 
variant with five additional nucleotides in the C-terminus (5-HT7s) 
was made by replacing an internal Hindlll-BamHl fragment with 
the corresponding fragment derived from another PCR product 
(Fig. 2). 
The correct sequence and orientation of the 5-HT7 gene were con-
firmed by sequencing across the junctions, using as primers synthetic 
oligonucleotides made to anneal close to the ends of the insert and 
internal primers. 
2.5. RT-PCR to determine the tissue distribution of the 5-HT7 variants 
cDNA was made with the Time Saver Kit (Pharmacia) from 
poly(A+) RNA (Clontech). With PCR, part of the 5-HT7 gene was 
amplified using primers that span the variable region of the gene. As 
5' primer FITC-labelled Org 3588 was used and as 3' primer 
Org 2901. The FITC-labelled PCR products were separated on a pol-
yacrylamide sequencing gel and analysed with the ALF DNA se-
quencer (Pharmacia Biotech). 
2.6. Southern blot hybridization 
Southern blots with human genomic DNA, digested with various 
restriction enzymes, were obtained from Clontech. The filters were 
prehybridized for 30 min at 60°C in Express Hyb Hybridization sol-
ution (Clontech). Hybridization was performed overnight at 60°C in 
the same buffer with probe 1 (nucleotides 1-836) or probe 2 (nucleo-
tides 836-1258). The probe was labelled using Ready To Go DNA 
labelling beads (-dCTP) (Pharmacia Biotech) according to the manu-
facturer's protocol. The filter was washed 2 times for 30 min each in 
2XSSC/0.1% SDS at 60°C and 2 times for 30 min each in 1 XSSC/ 
0.1% SDS. 
2.7. Cell culture and expression of the 5-HT'/ gene variants in 
NIH-3T3 cells 
NIH-3T3 cells were obtained from the ATCC and maintained at 
37°C in a humidified atmosphere (5% C02) as a monolayer culture in 
Dulbecco's Modified Eagles Medium/Hams F12 (1:1 mix) supple-
mented with 10% fetal calf or fortified bovine calf serum (Hyclone). 
To express the cloned genes, the expression constructs of the 5-HT7 
and 5-HT7s genes were transfected into NIH-3T3 cells using Trans-
fectam Reagent (Promega) together with the plasmid pAG60MTn, 
which encodes resistance to Geneticin (Gibco, NY). Transformed 
clones were selected in the presence of 600 |xg/ml Geneticin. Mem-
branes prepared from pools of transfected cells were analysed for 
expression of 5-HT7 receptors by a ligand-binding assay using the 
radiolabelled ligand [3H]LSD. For both splice variants, single-cell 
clones were selected by the limiting dilution method. 
2.8. Membrane preparation and radioligand-binding assay 
Cells were grown to confluency and then harvested in phosphate-
buffered saline containing 1 mM EDTA. The cells were centrifuged at 
500Xg for 10 min and the pellets were stored at —70°C until use. 
Immediately before the assay, the pellet was thawed, resuspended in 
assay buffer, and homogenised before addition to the reaction mix-
ture. A small aliquot of the final homogenate was taken for determi-
nation of protein concentration using the method of Bradford (Bio-
Rad reagent). 
Assays were performed in a total volume of 500 u.1 which consisted 
of 100 |o.l of radioligand ([3H]LSD or [3H]5-HT), 300 itl of cell sus-
pension and 100 jj.1 of either assay buffer (total binding) or clozapine 
(10- 5 M) (non-specific binding). Incubations were carried out at room 
temperature in the dark for 90 min. Assays were terminated by rapid 
vacuum filtration over glass-fiber filters. Filters were soaked in 0.1% 
polyethyleneimine before use. Filters were dried, transferred to 1.25 
ml Microscint-20 and counted in a TopCount. 
2.9. Measurement of cAMP formation 
NIH-3T3 cells transfected with either the human 5-HT 7 L or 5-HT7s 
construct were seeded on poly-L-lysine-coated 12-well plates (5X104 
cells per well). The cells were grown for 1 day in 1 ml of culture 
medium with 10%o fortified calf serum, Hyclone). After removal of 
the medium the wells were washed twice with 1 ml of serum-free 
culture medium and incubated for 30 min with 900 ui of serum-free 
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Fig. 3. Southern blot analysis of the human 5-HT7 receptor gene. Human genomic DNA (10 itg) was digested with the various restriction en-
zymes indicated. Two different probes were used: (1) a 836-bp fragment derived from the 5' -end (right panel), and (2) a 422-bp fragment cor-
responding to the 3' end of the receptor (left panel). Lane numbers indicate the the restriction enzymes used to digest the DNA. Lane 1, 
EcoRI; lane 2, Hindlll; lane 3, BamHI; lane 4, PstI; lane 5, Bgh. Numbers on the left refer to DNA size markers. 
medium that contained 0.5 mM IBMX. 5-HT (10X final concentra-
tion) was added in a volume of 100 ill of culture medium. The experi-
ment was terminated by taking 500 ul of extracellular medium for 
assessment of cAMP formation using a cyclic AMP radioimmuno-
assay kit (Immunotech International). 100 ul of standards or samples 
was transferred to antibody-coated tubes and 500 ul of [125I]cAMP 
tracer was subsequently added. All tubes were incubated for 18 h at 
4°C. After an 18 h incubation the contents of all tubes were removed. 
The radioactivity left in the tubes was determined in a gamma coun-
ter. 
3. Results and discussion 
To identify 5-HT7 receptor variants in human brain, reverse 
transcriptase (RT)-PCR was performed with several sets of 5-
HT7-specific primers and poly(A
+) mRNA extracted from 
human hypothalamus. The primers were designed on the basis 
of a published 5-HT7 receptor sequence [8]. Two types of 5-
HT7 receptor sequences were amplified that were subcloned 
into the vector pCRII for sequencing. 
One of the cDNAs (referred to as 5-HT7L, 'L' for long) 
contained an open reading frame of 1335 bp coding for a 5-
HT7 receptor with an identical sequence as the 5-HT7 se-
quence reported by Bard et al. [8]. The sequence of the second 
cDNA (termed 5-HT7s, 'S' for short) was identical to 5-HT7L, 
except for a 5-bp insertion (GTAAG) within the coding se-
quence at position 1296. This insertion results in a premature 
termination of the open reading frame at position 1297 (Fig. 
1). Hence, this novel 5-HT7 transcript encodes a truncated 5-
HT7 receptor that is virtually identical to the larger 5-HT7 
receptor (5-HT7L), except that it lacks the last 13 residues of 
the carboxy terminus of the 5-HT7L receptor. 
RT-PCR was used to examine the tissue distribution of the 
5-HT7L and 5-HT7S receptor variants in various human brain 
regions. Using 5-HT7-specific primers that do not discriminate 
I 
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Fig. 4. The effect of 5-HT on cAMP accumulation in NIH-3T3 cells 
expressing the two isoforms of the 5-HT7 receptor. Data are ex-
pressed as a percentage of the increase induced by forskolin. The in-
crease induced by forskolin was 8.6-fold for the long variant (closed 
symbols) and 9.4-fold for the short variant (open symbols). Data 
are from a representative experiment that was repeated twice with 
similar results. 
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Table 1 
Binding parameters for radioligand binding to the isoforms of the 5-HT7 receptor expressed in NIH-3T3 cells 
Receptor [3H]5-HT [3H]LSD 
(nM) (pmol/mg) (nM) (pmol/mg) 
5-HT7L 1.8 5.4 4 3.5 2.6 2 
5-HT7S 0.9 2.0 4 2.5 1.3 3 
between the two mRNAs, the amplified DNA fragments were 
analysed on acrylamide gels and analysed with an ALF auto-
mated fragment analyser (Pharmacia). The primers do not 
discriminate between the two variants, and therefore both 
types of mRNA were expected to be amplified equally well. 
In all tissues in which the 5-HT 7L variant was expressed, the 
5-HT7s isoform was co-expressed. Although the absolute level 
at which the 5-HT7 transcripts are present varied per tissue, 
the ratio in which the two types of mRNAs were expressed 
was roughly equal. In thymus, a tissue known not to express 
5-HT7 receptors, neither the 5-HT 7L nor 5-HT7g variants, 
could be detected. 
To determine whether the 5-HT7 receptor is a single copy 
gene, Southern blot analysis was performed on human ge-
nomic placenta DNA. The filters were hybridized with a 
probe specific for the 5' end of the 5-HT7 gene, and a dupli-
cate filter was hybridized with a 3' end specific probe. Since 
the 5' end probe overlaps a large intron, and contains no sites 
for any of the restriction enzymes used, this probe was ex-
pected to hybridize with two fragments in each lane, for a 
single copy gene. For the 3' end probe, one hybridizing 
band was expected in each lane in case of a single copy 
gene. As shown in Fig. 3, the 5' end probe yielded three 
hybridizing bands in all lanes, whereas two hybridizing bands 
are present when hybridized with the 3' end probe. These 
findings suggest that the human genome harbours at least 
two 5-HT7-like genes, that show a great deal of structural 
homology. This, in combination with the existence of two 
types of 5-HT7 transcripts in brain may suggest that the 
two 5-HT7 mRNAs are derived from two different genes. 
On the other hand, it may also be the case that the two tran-
scripts derive from the same gene by alternative mRNA splic-
ing. This possibility is supported by: (1) the fact that both the 
human and rat 5-HT-? receptor genes contain an intron at the 
position of the 5-bp insertion; (2) the presence of splice donor 
and splice acceptor sites at the junctions of the 5-bp insertion; 
and (3) the 100% sequence conservation between the short 
and long variants at the DNA level, even at all third base 
positions. If the two 5-HT7 receptor transcripts indeed derive 
by alternative splicing from one of the two hybridizing genes 
in the human genome, the second gene may code for a novel 
5-HT(7) subtype or a pseudogene. Elucidation of the genomic 
structure of both hybridizing DNA fragments from the hu-
man genome may shed some light on this matter. 
To investigate whether the two 5-HT7 cDNAs encode func-
tional 5-HT7 receptors, the cDNAs for the 5-HT 7 L and 5-
HT7g receptors were subcloned into the mammalian expres-
sion vector pkCREH and stably transfected into NIH-3T3 
cells. Using limiting dilution in combination with ligand-bind-
ing assays, a representative clone was selected for each of the 
two 5-HT7 receptor variants. Both clones express roughly 
similar densities of receptors (the difference in Bmax values is 
< 5). As shown in Fig. 4, the 5-HT 7L and 5-HT7s receptor 
isoforms were found to display similar affinities for both the 
antagonist [3H]LSD and the agonist [3H]5-HT. In Table 1, the 
binding parameters of both clones are presented. Saturation 
experiments with LSD were less reliable than those with 5-
HT. Therefore [3H]5-HT was used routinely as radioligand. 
The affinity of 5-HT for the short variant of the receptor was 
consistently higher than that for the long variant (n = A). K^ 
values are comparable to those obtained for the 5-HT 7 L var-
iant transiently transfected in COS-7 cells. 
The occurrence of two types of 5-HT7 receptors differing in 
their C-terminal tail is particularly interesting since studies 
with mutated and truncated receptors have shown that the 
intracellular C-terminal portion of G-protein-coupled recep-
tors is involved in G-protein coupling [11,15-17]. In this re-
spect, it is worth mentioning that for the 5-HT4 receptor, two 
variants have been described that vary in their C-terminus as 
a result of alternative splicing and that differ in both their G-
protein coupling and tissue distribution [3]. 
To determine whether the two 5-HT7 receptor variants cou-
ple to G-proteins, both receptor clones were exposed to var-
ious concentrations of 5-HT after which intracellular cAMP 
levels were measured. As shown in Fig. 4, 5-HT induced a 
dose-dependent increase in cAMP accumulation in both 
clones with similar EC5o values, i.e. 38 and 43 nM for the 
short and long variants, respectively. We compared the max-
imal level of activation with that induced by forskolin. In this 
manner we could correct for differences between the single-cell 
clones in their ability to activate adenylyl cyclase. The 5-HT7s 
receptor was clearly less effective in increasing cAMP. How-
ever, this can be explained by the lower level of receptor ex-
pression, since during the selection of the single-cell clones we 
observed that the effect on cAMP correlates well with the 
expression level (data not shown). Thus from the results 
from both radioligand-binding and functional experiments, 
we conclude that the 5-HT 7L and 5-HT7s receptors do not 
differ significantly with respect to their interaction with their 
endogenous ligand, when expressed in NIH-3T3 cells. We do 
not know yet whether other drugs may discriminate between 
the two isoforms. 
The identification of two 5-HT7 variants that are equally 
well expressed in brain and that are conserved in evolution 
from rodents to man [8-10] makes it tempting to speculate 
that there is an advantage to have a 5-HT 7 L and a 5-HT7s 
variant. Although our experiments do not show marked phar-
macological differences between the two receptors when ex-
pressed in NIH-3T3 cells, it should be noted that the two 
variants may behave differently with respect to pharmacolog-
ical properties such as coupling or desensitisation, when ex-
pressed in a different cellular context, e.g. the brain. 
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